Aktuellt
SENASTE
Q2 was overall strong with both sales and earnings topping our expectations (no consensus), with SyntheticMR growing sales 59% y/y. SyntheticMR mentioned it was pleasing to see that the causes that negatively affected Q1 were significantly reduced during the period. The results could potentially drive mid-single-digit positive revisions to our FY 2022 sales estimates.
LÄS MER
